{"SPADE_N_15132": {"Sequence Information": {"Peptide Name": "Psammosilenin B", "Sequence": "GFVPFTIP", "Sequence Length": 8, "Biological Activity": ["Anticancer"], "Binding Target": "1. Membrane Protein", "Source": "1. Psammosilene tunicoides", "Gene": "", "PDB ID": "", "UniProt Entry": [], "Literature": [{"Title": "Synthesis, characterization and anticancer screening of psammosilenin B: A cyclic octapeptide.", "Pubmed ID": "", "Reference": "Asian J Chem. 2015;27:1153–1156", "Author": "Shinde NV, Dhake AS, Haval KP", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/"}], "Mass": 877.04, "PI": 5.53, "Net Charge": 0, "Hydrophobicity": 1.25, "Frequent Amino Acids": "FPG", "Absent Amino Acids": "ACDEHKLMNOQRSUWY", "Basic Residues": 0, "Acidic Residues": 0, "Hydrophobic Residues": 4, "Polar Residues": 4, "Positive Residues": 0, "Negative Residues": 0, "SPADE ID": "SPADE_N_15132", "Similar Sequences": [{"SPADE_ID": "SPADE_N_12194", "Similarity": 1.0, "Sequence": "MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFV"}, {"SPADE_ID": "SPADE_UN_15161", "Similarity": 1.0, "Sequence": "LLMVNEATRFQTVSGFV"}, {"SPADE_ID": "SPADE_UN_17486", "Similarity": 1.0, "Sequence": "PYGFV"}], "Hemolytic Activity": "", "Target Organism": "Human lymphoblastic leukemia CCRF-CEM(80-90% Inhibition=10µM),Human promyelocytic leukemia HL-60(90-100% Inhibition=10µM),Human myelogenous leukemia K562(70-80% Inhibition=10µM),Human lymphoblastic leukemia Molt-4(90-100% Inhibition=10µM),Human Myeloma cells RPMI-8226(90-100% Inhibition=10µM),Human lung carcinoma A549(40-50% Inhibition=10µM),Human lung adenocarcinoma NCI-H23(30-40% Inhibition=10µM),Human lung adenocarcinoma NCI-H3122(10-20% Inhibition=10µM),Human lung carcinoma NCI-H460(40-50% Inhibition=10µM),Human lung adenocarcinoma NCI-H522(40-50% Inhibition=10µM),Human colon adenocarcinoma HCT 116(80-90% Inhibition=10µM),Human colon adenocarcinoma HCT-15(20-30% Inhibition=10µM),Human colon adenocarcinoma HT29(20-30% Inhibition=10µM),Human colon adenocarcinoma SW620(30-40% Inhibition=10µM),Human Astrocytoma SF-268(20-30% Inhibition=10µM),Human glioblastoma SF-295(20-30% Inhibition=10µM),Human Astrocytoma SF-539(10-20% Inhibition=10µM),Human glioblastoma U251-MG(40-50% Inhibition=10µM),Human skin melanoma SK-MEL-2(10-20% Inhibition=10µM),Human skin melanoma SK-Mel-28(20-30% Inhibition=10µM),Human melanoma UACC-62(30-40% Inhibition=10µM),Human breast adenocarcinoma MDA-MB-435(20-30% Inhibition=10µM),Human ovarian adenocarcinoma IGROV1(30-40% Inhibition=10µM),Human epithelial carcinoma OVCAR-3(40-50% Inhibition=10µM),Human epithelial carcinoma OVCAR-5(10-20% Inhibition=10µM),Human ovarian cancer NCI/ADR-RES(30-40% Inhibition=10µM),Human ovarian adenocarcinoma SK-OV-3(20-30% Inhibition=10µM),Human renal carcinoma A498(70-80% Inhibition=10µM),Human renal adenocarcinoma ACHN(40-50% Inhibition=10µM),Human renal carcinoma UO-31(60-70% Inhibition=10µM),Human prostate adenocarcinoma PC-3(90-100% Inhibition=10µM),Human prostate cancer DU145(10-20% Inhibition=10µM),Human breast adenocarcinoma MCF-7(30-40% Inhibition=10µM),Human breast adenocarcinoma MDA-MB-231(70-80% Inhibition=10µM),Human breast carcinoma HS 578T(40-50% Inhibition=10µM)"}}}